Curis Reports Q3 2026 Financial Results and Emavusertib Clinical Data Updates
Curis, Inc. (CRIS) reported its third-quarter 2026 financial results, highlighting clinical progress for its lead oncology candidate, emavusertib. In the TakeAim Lymphoma study for Primary CNS Lymphoma (PCNSL), the combination therapy achieved an 86% response rate in BTKi-naive patients, significantly outperforming published monotherapy benchmarks of 39% to 67%. The company also reported a 26% response rate in salvage-line patients who had previously progressed on BTK inhibitor monotherapy. Financially, Curis reported a net loss of $8.1 million for the quarter, with a nine-month net loss of $40.9 million. Despite increased clinical costs, the company maintains a cash position of $5 million as of September 30, 2026, which management expects will fund operations into 2027. Looking ahead, the company anticipates first proof-of-concept data for emavusertib in Chronic Lymphocytic Leukemia (CLL) by the end of 2026 and aims for an NDA submission in PCNSL by 2028.
Topics: cash runway clinical trial results net loss R&D expenses